LABELS · 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

CEFEPIME HYDROCHLORIDE AND DEXTROSE

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-04-07
Captured: 2026-09-09T23:37:54.830918+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae when the infection is severe, or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Full extracted label fields

application numbers

NDA050821

boxed warning exact

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57517a0e-ec1b-4605-a7cc-7e3801158ec9

generic names

CEFEPIME HYDROCHLORIDE

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

indications and usage exact

1 INDICATIONS AND USAGE Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae when the infection is severe, or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

indications and usage tables exact

is original packager

true

manufacturer names

B. Braun Medical Inc.

matched search terms

malignancy

package ndcs

0264-3193-11
0264-3195-11

product ndcs

0264-3193
0264-3195

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1665088
1665093

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00500.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 704
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 0

current approval status

not_reconciled

duplicate text group

dup-81e99aa3c23a76e1e86f

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-ceb050f19107376c4957

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 112
end exclusive: true
exact text: is a cephalosporin antibacterial indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 70

qualifier mentions

context exact
icated intra-abdominal infections (used in combination with metronidazole) ( 1.5 )
kind
biomarker
polarity
not_inferred
span
end
500
end exclusive
true
exact text
metronidazole) ( 1
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
482
context exact
ctions ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 )
kind
regimen
polarity
not_inferred
span
end
500
end exclusive
true
exact text
in combination with metronidazole) ( 1
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
462

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 504
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 )
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1029
end exclusive: true
exact text: cated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated wit
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 305

current approval status

not_reconciled

duplicate text group

dup-ed5cd1132c598f7c25b8

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-cec2db1c61b47c9a5281

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 829
end exclusive: true
exact text: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 505

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1037
end exclusive: true
exact text: jection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concur
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 630

current approval status

not_reconciled

duplicate text group

dup-dab3164a82c81f18c406

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-492f5ecd05dd5e449481

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 837
end exclusive: true
exact text: ( 1.6 )
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 830

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1328
end exclusive: true
exact text: and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at hi
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 638

current approval status

not_reconciled

duplicate text group

dup-7442b33fdf72c8ebbd8b

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-b0e03e46067a8848cceb

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 910
end exclusive: true
exact text: is indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 898

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1128
end exclusive: true
exact text: 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 838

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1510
end exclusive: true
exact text: of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 929

current approval status

not_reconciled

duplicate text group

dup-f29b1717291b4b5947ee

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-43934a2e11ebdaeddb7a

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 1255
end exclusive: true
exact text: is indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1243

qualifier mentions

context exact
enic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients.
kind
regimen
polarity
not_inferred
span
end
1309
end exclusive
true
exact text
as monotherapy is indicated for empiric treatment of febrile neutropenic patients
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
1228

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1310
end exclusive: true
exact text: 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1129

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1799
end exclusive: true
exact text: robacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonep
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1111

current approval status

not_reconciled

duplicate text group

dup-72623bb383d4bbb4ac45

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-23d65403c08da48ce6f1

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1599
end exclusive: true
exact text: In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1311

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1920
end exclusive: true
exact text: t bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infect
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1400

current approval status

not_reconciled

duplicate text group

dup-bdd88eedfecbf4ab2f96

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-1ceeebe87dbe3c91a424

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1720
end exclusive: true
exact text: Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ].
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1600

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2431
end exclusive: true
exact text: e or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae when the infection is severe, or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylo
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1521

current approval status

not_reconciled

duplicate text group

dup-90b8c51357b96a7f3810

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-d73b50375b751e093226

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 1865
end exclusive: true
exact text: is indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1853

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2231
end exclusive: true
exact text: 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection and Dextrose Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae when the infection is severe, or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 1721

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2711
end exclusive: true
exact text: , or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Esc
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2032

current approval status

not_reconciled

duplicate text group

dup-4e7352e185aaa48c2c40

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-9bfa997ed0e8bf92fbde

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 2343
end exclusive: true
exact text: is indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2331

qualifier mentions

context exact
skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes .
kind
biomarker
polarity
not_inferred
span
end
2489
end exclusive
true
exact text
methicillin-susceptible strains only) or St
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
2446

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2511
end exclusive: true
exact text: 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection and Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes .
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2232

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · positive indication candidate

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3083
end exclusive: true
exact text: Dextrose Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection an
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2312

current approval status

not_reconciled

duplicate text group

dup-c0ca7229d5716eded17c

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-5aa0d609ba2c76ce4c35

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

end: 2613
end exclusive: true
exact text: is indicated
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2601

qualifier mentions

context exact
icated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Kleb
kind
biomarker
polarity
not_inferred
span
end
2725
end exclusive
true
exact text
metronidazole) caused by Escherichia coli
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
2683
context exact
indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ].
kind
regimen
polarity
not_inferred
span
end
2842
end exclusive
true
exact text
in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides
label id
8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start
2663

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2883
end exclusive: true
exact text: 1.5 Complicated Intra-abdominal Infections Cefepime for Injection and Dextrose Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ].
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2512

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3430
end exclusive: true
exact text: etronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis [ see Clinical Studies (14.2) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibilit
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2684

current approval status

not_reconciled

duplicate text group

dup-d1194ad8363c8c3e145b

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-ae17f3589c9c6cac54d9

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 3230
end exclusive: true
exact text: 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 2884

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3492
end exclusive: true
exact text: other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 3031

current approval status

not_reconciled

duplicate text group

dup-8f6e8148f5998cd093e0

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-90c66df0490a81eef5a1

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 3364
end exclusive: true
exact text: When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 3231

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA050821

brand names

CEFEPIME HYDROCHLORIDE AND DEXTROSE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3492
end exclusive: true
exact text: roven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 3165

current approval status

not_reconciled

duplicate text group

dup-2638525ed62c1aedf7ed

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME HYDROCHLORIDE

ind-span-170b6546757cfa76d8c7

label id

8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 3492
end exclusive: true
exact text: In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 8b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 94f85fb9f0bfd2e0f1d8a242fc27736f11f80074b5ba0e5eb474b6b6812d16a4
start: 3365

source url

https://api.fda.gov/drug/label.json?search=id%3A%228b4b5fb9-6be2-40c8-a8ef-60a9d7967e3e%22

spl effective date

2026-04-07

spl set id

57517a0e-ec1b-4605-a7cc-7e3801158ec9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice